StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15−0.00 (-1.72%)

Close on Nov 18, 2026Market cap $10.06MP/E –Yield –

TScan Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

TScan Therapeutics's total debt was $32.78M at Jun 30, 2026. For fiscal 2025 it was $32.53M, up 1.4% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$32.53M+1.4%
FY2024Dec 31, 2024$32.07M+6.7%
FY2023Dec 31, 2023$30.05M+2.6%
FY2022Dec 31, 2022$29.29M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$32.78M+1.5%
Q1 FY2026Mar 31, 2026$32.65M+1.5%
Q4 FY2025Dec 31, 2025$32.53M+1.4%
Q3 FY2025Sep 30, 2025$32.41M+5.8%
Q2 FY2025Jun 30, 2025$32.30M+6.1%
Q1 FY2025Mar 31, 2025$32.18M+6.4%
Q4 FY2024Dec 31, 2024$32.07M+6.7%
Q3 FY2024Sep 30, 2024$30.65M+2.3%
Q2 FY2024Jun 30, 2024$30.45M+2.4%
Q1 FY2024Mar 31, 2024$30.25M+2.5%
Q4 FY2023Dec 31, 2023$30.05M+2.6%
Q3 FY2023Sep 30, 2023$29.95M+3.0%
Q2 FY2023Jun 30, 2023$29.72M–
Q1 FY2023Mar 31, 2023$29.50M–
Q4 FY2022Dec 31, 2022$29.29M–
Q3 FY2022Sep 30, 2022$29.07M–

More TScan Therapeutics figures

See a number that looks wrong?